Twist Bioscience Corp - Asset Resilience Ratio
Twist Bioscience Corp (TWST) has an Asset Resilience Ratio of 7.35% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See TWST working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how Twist Bioscience Corp's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see TWST current and non-current assets.
Liquid Assets Composition Over Time
This chart breaks down Twist Bioscience Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Twist Bioscience Corp long-term investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $49.40 Million | 7.35% |
| Total Liquid Assets | $49.40 Million | 7.35% |
Asset Resilience Insights
- Limited Liquidity: Twist Bioscience Corp maintains only 7.35% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Twist Bioscience Corp Industry Peers by Asset Resilience Ratio
Compare Twist Bioscience Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 16.06% |
|
Genscript Biotech Corporation
F:G51 |
Biotechnology | 13.79% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
89bio Inc
NASDAQ:ETNB |
Biotechnology | 71.60% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 2.66% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
Annual Asset Resilience Ratio for Twist Bioscience Corp (2016–2025)
The table below shows the annual Asset Resilience Ratio data for Twist Bioscience Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-09-30 | 7.69% | $49.38 Million | $641.86 Million | -0.46pp |
| 2024-09-30 | 8.15% | $50.08 Million | $614.32 Million | +1.72pp |
| 2023-09-30 | 6.43% | $49.94 Million | $776.40 Million | -6.70pp |
| 2022-09-30 | 13.14% | $126.28 Million | $961.38 Million | +11.42pp |
| 2021-09-30 | 1.71% | $12.03 Million | $702.10 Million | -47.51pp |
| 2020-09-30 | 49.22% | $196.34 Million | $398.88 Million | +0.36pp |
| 2019-09-30 | 48.86% | $91.37 Million | $186.99 Million | -- |
| 2018-09-30 | 0.00% | $0.00 | $115.79 Million | -- |
| 2017-09-30 | 36.16% | $30.98 Million | $85.66 Million | +0.43pp |
| 2016-09-30 | 35.73% | $27.32 Million | $76.46 Million | -- |
About Twist Bioscience Corp
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo … Read more